ERCC1 mRNA levels can predict the response to cisplatin-based concurrent chemoradiotherapy of locally advanced cervical squamous cell carcinoma

BACKGROUND: The purpose of this study was to investigate whether the excision repair cross-complementation group 1 (ERCC1) mRNA expression could predict treatment response of patients with locally advanced cervical squamous cell carcinoma (LACSCC) who underwent cisplatin-based concurrent chemoradiot...

Descripción completa

Detalles Bibliográficos
Autores principales: Bai, Zhou-lan, Wang, Yan-yang, Zhe, Hong, He, Jian-li, Hai, Ping
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2012
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3536645/
https://www.ncbi.nlm.nih.gov/pubmed/23259415
http://dx.doi.org/10.1186/1748-717X-7-221

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3536645/
https://www.ncbi.nlm.nih.gov/pubmed/23259415
http://dx.doi.org/10.1186/1748-717X-7-221

Ejemplares similares